RecruitingPhase 4NCT07457060

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine

An Open-labelled, Randomized, Controlled, Clinical Trial to Evaluate the Immunogenicity and Tolerability of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine

Sponsor

Sinovac Biotech Co., Ltd

Enrollment

480 participants

Start Date

Nov 27, 2025

Study Type

INTERVENTIONAL

Conditions

Poliomyelitis

Summary

The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes

Eligibility

Min Age: 56 DaysMax Age: 84 Days

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 1wIPV+2sIPV, a biological treatment called 2wIPV+1sIPV, and others for people with poliomyelitis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 56 Days to 84 Days.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICAL2wIPV+1sIPV

First 2 doses: wIPV. 3rd dose: sIPV In each intervention group, two-thirds of the participants will receive the full-course vaccination via intramuscular injections, while the remaining one-third will receive it via subcutaneous injections.

BIOLOGICAL1wIPV+2sIPV

1st dose: wIPV. 2nd \& 3rd doses: sIPV In each intervention group, two-thirds of the participants will receive the full-course vaccination via intramuscular injections, while the remaining one-third will receive it via subcutaneous injections.

BIOLOGICAL3wIPV

three doses of wIPV with an interval of 28 days (+14 days) between doses; In each intervention group, two-thirds of the participants will receive the full-course vaccination via intramuscular injections, while the remaining one-third will receive it via subcutaneous injections.

BIOLOGICAL3sIPV

Three doses of sIPV with an interval of 28 days (+14 days) between doses. In each intervention group, two-thirds of the participants will receive the full-course vaccination via intramuscular injections, while the remaining one-third will receive it via subcutaneous injections.

Locations(3)

Centennial Clindev Research and Development of Medical Sciences

Kawit, Cavite, Philippines

Iloilo Doctors' Hospital

Iloilo City, Philippines

Health Index Multispecialty Clinic - Research and Development on Medical Sciences

Imus, Philippines

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07457060

Related Trials

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

NCT056544673 locations

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

NCT073542693 locations

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

NCT068954863 locations

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

NCT056441841 location

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

NCT065772981 location